Pharmacological properties and clinical efficacy of bempedoic acid (NEXLETOL® tablets 180 mg) for the treatment of hypercholesterolemia

Q: What is the clinical evidence from this study?

Study design: Review. Population: Hypercholesterolemia and familial hypercholesterolemia. Intervention: Bempedoic acid vs. Placebo. Primary outcome: Percent change in LDL-C from baseline to Week 12 (Japanese Phase III confirmatory trial) and 4-component MACE (international CV outcomes trial) (MD -21.78%, 95% CI -26.71 to -16.85, p=<0.001).

Q: What does this research mean for the field?

Bempedoic acid effectively lowers LDL cholesterol and reduces the risk of cardiovascular events in patients with hypercholesterolemia, including statin-intolerant individuals, while avoiding muscle-related side effects due to its liver-specific activation. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Q: What question did this study set out to answer?

To summarize the pharmacological mechanisms, preclinical efficacy, pharmacokinetics, and clinical trial outcomes of bempedoic acid for managing hypercholesterolemia.

Tomohisa Suzuki; Hitomi Fujita; Hiromi Maune

doi:10.1254/fpj.26059

August 31, 2026Folia Pharmacologica JaponicaOpen Access

Pharmacological properties and clinical efficacy of bempedoic acid (NEXLETOL® tablets 180 mg) for the treatment of hypercholesterolemia

View Full Paper

Ask AI

Bookmark

Share

Key result

Bempedoic acid lowers LDL-C ~22% and reduces major cardiovascular events in statin-intolerant patients.

MD -21.78%
95% CI -26.71 to -16.85
P<0.001

Why the study?

Does bempedoic acid 180 mg once daily reduce LDL-C levels and cardiovascular events in patients with hypercholesterolemia who have an inadequate response to statins or are statin-intolerant?

Key Points

To summarize the pharmacological mechanisms, preclinical efficacy, pharmacokinetics, and clinical trial outcomes of bempedoic acid for managing hypercholesterolemia.
Reviewed in vitro and in vivo studies examining prodrug activation by ACSVL1 and direct competitive inhibition of ATP citrate lyase (ACL).
Assessed preclinical pharmacology in diet-induced hamster, ApoE knockout mouse, and LDLR-deficient minipig models.
Summarized pharmacokinetic parameters across healthy adults and organ impairment groups, alongside findings from domestic and global phase III clinical trials.
Bempedoic acid active CoA ester competitively inhibited human ACL with an inhibition constant (Ki) of 2 μM, inducing LDLR expression via SREBP2 without eliciting toxicity in skeletal muscle cells lacking ACSVL1.
Preclinical treatment reduced LDL-C by up to ~71% in hamsters (30 mg/kg/day) and decreased total aortic lesion area and elevated lesion area by approximately 58% in minipigs.
Clinical evaluations demonstrated early and sustained LDL-C reduction regardless of statin responsiveness, and a phase III trial confirmed reduced cardiovascular event risk in statin-intolerant patients.

Structured PICO

Does bempedoic acid 180 mg once daily reduce LDL-C levels and cardiovascular events in patients with hypercholesterolemia who have an inadequate response to statins or are statin-intolerant?

P

Population

Narrative new-drug review summarizing preclinical models, pharmacokinetic studies, Japanese Phase III trials (n=96 and n=130), and international Phase III trials (including CLEAR Outcomes, n=13,970) of bempedoic acid in patients with hypercholesterolemia.

I

Intervention

Bempedoic acid 180 mg oral once daily (administered alone or added to background lipid-lowering therapy including statins and/or ezetimibe)

C

Comparator

Placebo (in randomized Phase III trials)

O

Outcome

Percent change from baseline to Week 12 in LDL-C (Japanese and international Phase III lipid trials) and time to first occurrence of 4-component MACE (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization) in the international cardiovascular outcomes trialsurrogate

Main Result

Mean Difference: -21.78 (95% CI -26.71–-16.85)

Absolute Event Rate: -25.25% vs -3.46%

p-value: p=<0.001

Limitations

Pharmacokinetics in patients with severe hepatic impairment (Child-Pugh C) have not been studied, and unbound exposure may increase.
Concomitant administration with statins increases statin Cmax and AUC, requiring caution regarding muscle-related adverse events.
Inhibition of renal tubular OAT2 by bempedoic acid can increase serum uric acid levels and risk of hyperuricemia or gout.
Pharmacokinetics in patients with severe hepatic impairment (Child-Pugh C) have not been evaluated.
Co-administration with statins (atorvastatin, rosuvastatin, simvastatin, pravastatin) increases statin plasma exposure (Cmax and AUC), warranting monitoring for muscle-related adverse events.
Bempedoic acid inhibits renal OAT2 and is associated with increased serum uric acid levels and hyperuricemia.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Bempedoic acid, a liver-selective ATP citrate lyase inhibitor newly approved in Japan, significantly lowers LDL-C by ~22% in Japanese patients and reduces major adverse cardiovascular events (HR 0.87) in statin-intolerant patients without causing direct skeletal muscle toxicity.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Suzuki et al. (2026) conducted a review in Hypercholesterolemia and familial hypercholesterolemia. Bempedoic acid vs. Placebo was evaluated on Percent change in LDL-C from baseline to Week 12 (Japanese Phase III confirmatory trial) and 4-component MACE (international CV outcomes trial) (MD -21.78%, 95% CI -26.71 to -16.85, p=<0.001).

synapsesocial.com/papers/6a9934b4636c6408cfa7c7b6 https://doi.org/10.1254/fpj.26059

View Full Paper

Ask AI

Bookmark

Share

Pharmacological properties and clinical efficacy of bempedoic acid (NEXLETOL® tablets 180 mg) for the treatment of hypercholesterolemia

Key Points

Structured PICO

Main Result

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Pharmacological properties and clinical efficacy of bempedoic acid (NEXLETOL® tablets 180 mg) for the treatment of hypercholesterolemia

Key Points

Structured PICO

Main Result

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading